## **Drug Interactions with Oral Contraceptives and HIV Medications 2015**

John J Faragon, PharmD, BCPS, AAHIVP

ARV	Effect on Contraceptive	Recommendation with Oral Contraceptive	Recommendation with DMPA	Recommendation with Etonogestrel Implant
NNRTIs				
Efavirenz	Ethinyl Estradiol/ Norgestimate:  • No change in ethinyl estradiol  • ↓ active metabolites of norgestimate  • levonorgestrel AUC ↓ 83%;  • norelgestromin AUC ↓ 64% Implant:  • ↓ etonogestrel Emergency Contraception:  • Levonorgestrel AUC ↓ 58%	Use alternative contraceptive method.	No additional contraceptive needed.	Use alternative or additional contraceptive method.
Etravirine	Ethinyl estradiol:  • AUC ↑ 22%  Norethindrone  • No significant change	No additional contraceptive needed.	No additional contraceptive needed.	No additional contraceptive needed.
Nevirapine	Ethinyl estradiol:  • AUC ↓ 20%  Norethindrone:  • AUC ↓ 19%  DMPA:  • No significant change	Consider alternative method or reliable barrier contraception in addition	No additional contraceptive needed.	Consider alternative method or reliable barrier contraception in addition.
Rilpivirine	Ethinyl estradiol:  • AUC ↑ 14%  Norethindrone:  • No significant change	No additional contraceptive needed.	No additional contraceptive needed.	No additional contraceptive needed.

ARV	Effect on Contraceptive	Recommendation with Oral Contraceptive	Recommendation with DMPA	Recommendation with Etonogestrel Implant	
Ritonavir Boosted Protease Inhibitors					
Atazanavir/rtv	Ethinyl estradiol: • AUC ↓ 19% ↑ Norgestimate: • AUC ↑ 85%		No additional contraceptive needed.	Consider alternative method or reliable barrier contraception in addition.	
Darunavir/rtv	Ethinyl estradiol: • AUC ↓ 44% Norethindrone: • AUC ↓ 14%		No additional contraceptive needed.	Consider alternative method or reliable barrier contraception in addition.	
Fosamprenavir/rtv	Ethinyl estradiol: • AUC ↓ 37% Norethindrone: • AUC ↓ 34%	Use alternative or additional contraceptive method.	No additional contraceptive needed.	Consider alternative method or reliable barrier contraception in addition.	
Lopinavir/rtv	Ethinyl estradiol:  • AUC ↓ 42%  Norethindrone:  • AUC ↓ 17%	Use alternative or additional contraceptive method.	No additional contraceptive needed.	Consider alternative method or reliable barrier contraception in addition.	
Saquinavir/rtv	Ethinyl estradiol: • Expected decrease	Use alternative or additional contraceptive method.	No additional contraceptive needed.	Consider alternative method or reliable barrier contraception in addition,	
Tipranavir/rtv	Ethinyl estradiol:  • AUC ↓ 48%  Norethindrone:  • No significant change		No additional contraceptive needed.	Consider alternative method or reliable barrier contraception in addition.	

ARV	Effect on Contraceptive	Recommendation for Oral Contraceptive	Recommendation for DMPA	Recommendation for Etonogestrel Implant	
Protease Inhibitors without Ritonavir					
Atazanavir	Ethinyl estradiol: • AUC ↑ 48% Norgethindrone: • AUC ↑ 110%	No additional contraceptive needed Oral contraceptive should contain ≤ 30 mcg ethinyl estradiol or use alternative method. Oral contraceptives containing <25mcg of ethinyl estradiol or those with progestins other than norethindrone or norgestimate have not been studied	No additional contraceptive needed.	No additional contraceptive needed.	
Fosamprenavir	Ethinyl Estradiol /Norethindrone:  ↓ Amprenavir AUC 22%, Cmin 20%	Use alternative contraceptive method. Use of fosamprenavir with ethinyl estradiol and norethindrone may lead to loss of virologic response.	No additional contraceptive needed.	Use alternative or additional contraceptive	
Indinavir	Ethinyl estradiol: • AUC ↑ 25% Norethindrone: • AUC ↑ 26%	No additional contraceptive needed.	No additional contraceptive needed.	No additional contraceptive needed	
Nelfinavir	Ethinyl estradiol:  • AUC↓ 47%  Norethindrone:  • AUC ↓ 18%	Use alternative or additional contraceptive	No additional contraceptive needed.	Use alternative or additional contraceptive	

CCR5 Antagonist				
ARV	Effect on Contraceptive	Recommendation for Oral Contraceptive	Recommendation for DMPA	Recommendation for Etonogestrel Implant
CCR5 Antagonist				
Maraviroc	No significant effect on ethinyl estradiol or levonorgestrel	No additional contraceptive needed.	No additional contraceptive needed.	No additional contraceptive needed
ARV	Effect on Contraceptive	Recommendation for Oral Contraceptive	Recommendation for DMPA	Recommendation for Etonogestrel Implant
Integrase Inhibitors				
Raltegravir	No significant effect	No additional contraceptive needed.	No additional contraceptive needed.	No additional contraceptive needed
Dolutegravir	No significant effect on norgestimate or ethinyl estradiol	No additional contraceptive needed.	No additional contraceptive needed.	No additional contraceptive needed
Elvitegravir/cobicistat	Ethinyl Estradiol: • AUC ↓ 25% Noregstimate: • AUC ↑ 230%	No additional contraceptive needed.	No additional contraceptive needed.	No additional contraceptive needed

Disclaimer: The information contained in this table has been developed from various resources, including FDA product information, and from recent DHHS Guidelines. While the tables contained in this guide are complete based upon references reviewed, there may be other medications that may also require additional contraceptive methods. Please consult additional resources as needed.